Last reviewed · How we verify
Zoladex and Casodex
Zoladex suppresses testosterone production via GnRH agonism, while Casodex blocks androgen receptors, together providing dual hormonal blockade for androgen-dependent cancers.
Zoladex suppresses testosterone production via GnRH agonism, while Casodex blocks androgen receptors, together providing dual hormonal blockade for androgen-dependent cancers. Used for Metastatic prostate cancer, Locally advanced prostate cancer, Endometriosis.
At a glance
| Generic name | Zoladex and Casodex |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | GnRH agonist (Zoladex) and androgen receptor antagonist (Casodex) |
| Target | GnRH receptor (Zoladex); androgen receptor (Casodex) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Zoladex (goserelin) is a GnRH agonist that initially stimulates then suppresses luteinizing hormone and follicle-stimulating hormone, leading to castrate levels of testosterone. Casodex (bicalutamide) is a non-steroidal androgen receptor antagonist that blocks residual androgens and receptor signaling. Together, they provide maximal androgen deprivation therapy (MAD) by eliminating both androgen production and receptor activation.
Approved indications
- Metastatic prostate cancer
- Locally advanced prostate cancer
- Endometriosis
- Uterine fibroids (Zoladex only)
Common side effects
- Hot flashes
- Gynecomastia
- Erectile dysfunction
- Fatigue
- Injection site reaction (Zoladex)
- Diarrhea (Casodex)
- Hepatotoxicity
Key clinical trials
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (PHASE3)
- Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (PHASE3)
- Contributions to Hypertension With Androgen Deprivation Therapy (PHASE4)
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (PHASE2)
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (PHASE2)
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (PHASE2, PHASE3)
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoladex and Casodex CI brief — competitive landscape report
- Zoladex and Casodex updates RSS · CI watch RSS
- AstraZeneca portfolio CI